KOSDAQBiotech & Pharma308080

ViGenCell

₩5,850 0.00%2026-10-02 close

Market Cap

₩119.1B

Turnover

₩300M

Volume

50,000 shares

Shares out.

20.5M

PER

—

PBR

3.4×

EPS

-₩648

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Strong Trial Data, Revenue Test Looms

ViGenCell is pursuing conditional approval and a China licensing deal for its EBV-positive NK/T-cell lymphoma therapy VT-EBV-N, backed by long-term follow-up data and Korea's first advanced regenerative medicine treatment, while facing growing listing-maintenance pressure as its revenue-requirement grace period ends in 2026.

1
VT-EBV-N maintained a 4-year disease-free survival (DFS) rate of 95.0% and overall survival (OS) of 100% as presented at ASCO 2026.
2
On September 1, 2026, VT-EBV-N administration began at Yeouido St. Mary's Hospital as Korea's first approved advanced regenerative medicine treatment plan.
3
2025 revenue was only about KRW 22.67 million, far below the KOSDAQ revenue requirement of KRW 3 billion applicable from 2026, raising concerns about designation as an administrative issue stock.
4
Total equity fell for four consecutive years, from about KRW 89.6 billion in 2022 to about KRW 43.7 billion in 2025, reflecting accumulated losses.
5
Licensing negotiations with major Chinese pharmaceutical companies are ongoing, but the scope and structure of any deal remain undetermined.

Business structure

ViGenCell is an immune cell therapy developer with proprietary platforms including ViTier (antigen-specific cytotoxic T cells), ViRanger (gamma-delta T cell gene therapy), and ViMedier (cord blood-derived myeloid suppressor cells).

Its lead pipeline asset, VT-EBV-N, is an antigen-specific T cell therapy targeting Epstein-Barr virus (EBV)-positive extranodal NK/T-cell lymphoma, aimed at preventing relapse in high-risk patients who have achieved complete remission.

This indication is a rare hematologic cancer with a notably higher incidence in Asia; according to the International T-cell Lymphoma Project (ITCLP), EBV-positive extranodal NK/T-cell lymphoma accounts for 22.4% of Asian T/NK-cell lymphoma cases versus 5.1% in North America and 4.3% in Europe.

The company secured cell-processing facility approval for its 'V-Cell Center,' an advanced biopharmaceutical GMP facility, in December 2024, establishing in-house manufacturing and quality-control capability ahead of commercialization.

Building on this, VT-EBV-N administration began on September 1, 2026 under Korea's first approved advanced regenerative medicine treatment plan, filed by Catholic University of Korea's Yeouido St. Mary's Hospital, covering 15 high-relapse-risk complete-remission patients over a two-year period.

Next-generation pipeline assets include VC-302, targeting glioblastoma, and VC-420, targeting hepatocellular carcinoma, both based on an induced pluripotent stem cell (iPSC)-derived allogeneic CAR-NK platform, reflecting an effort to diversify beyond a single-asset profile.

The domestic NK/T-cell lymphoma treatment space is reported to lack a clearly established competing therapy, which the company views as an opportunity to secure early market position upon commercialization.

Revenue currently remains at the level of technology and service fees typical of a clinical-stage company, with meaningful product sales anticipated only after conditional approval.

Earnings trend

Quarterly revenue · Operating profit

25Q2₩8,001,000-₩2.4B25Q3₩14,051,000-₩6.3B25Q4₩300M-₩2.8B26Q1₩600M-₩2.5B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩0-₩18.2B2022₩0-₩20.1B2023₩300M-₩15.3B2024₩22,674,300-₩17.1B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	—	—	—
2025Q3	₩8,001,000	-₩2.4B	−30405.0%
2025Q4	₩14,051,000	-₩6.3B	−45073.8%
2026Q1	₩300M	-₩2.8B	−862.5%
2026Q2	₩600M	-₩2.5B	−444.0%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩0	-₩18.2B	-₩17.4B	—	−19.4%	10.9%
2023	₩0	-₩20.1B	-₩17.9B	—	−25.0%	13.4%
2024	₩300M	-₩15.3B	-₩14.1B	−5495.9%	−24.2%	16.1%
2025	₩22,674,300	-₩17.1B	-₩16.3B	−75453.1%	−37.3%	24.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-05

Earnings analysis

Consolidated revenue in 2025 was only about KRW 22.67 million, down from KRW 278.9 million in 2024, while the operating loss widened to about KRW 17.1 billion (2025) from KRW 15.3 billion in 2024.

Net loss attributable to owners was about KRW 16.3 billion in 2025, up from KRW 14.1 billion in 2024, and compares with KRW 17.9 billion in 2023 and KRW 17.4 billion in 2022 — a pattern of roughly KRW 17-20 billion annual losses persisting across four straight years.

Operating cash flow was also negative in every year shown, at about negative KRW 13.8 billion in 2025. Total equity has declined every year, from about KRW 89.6 billion in 2022 to KRW 71.5 billion in 2023, KRW 58.0 billion in 2024, and KRW 43.7 billion in 2025, reflecting mounting pressure from accumulated losses.

On a quarterly basis, revenue remained minimal through 2025Q3 (about KRW 8.0 million, with an operating loss of about KRW 2.4 billion) and 2025Q4 (about KRW 14.1 million, operating loss about KRW 6.3 billion), before jumping to about KRW 328.7 million in 2026Q1 and further to about KRW 571.2 million in 2026Q2 — levels that approach or exceed the KOSDAQ half-year revenue threshold of KRW 700 million.

Even so, operating losses remained sizable in the same period, at about KRW 2.8 billion in 2026Q1 and KRW 2.5 billion in 2026Q2, indicating the revenue increase has not yet translated into an improved bottom line.

The debt ratio rose from 10.9% in 2022 to 24.1% in 2025, though the absolute level remains low, meaning the pace of equity erosion — rather than short-term debt burden — remains the key balance-sheet watch item.

Industry analysis

EBV-positive NK/T-cell lymphoma is a rare hematologic cancer that, according to the International T-cell Lymphoma Project (ITCLP), accounts for 22.4% of Asian T/NK-cell lymphoma cases — markedly higher than in North America or Europe — with particularly high incidence across Korea, China, and Japan.

The company states this indication has a high relapse rate and lacks a clearly established competing therapy domestically, a condition viewed as favorable for securing early market position upon commercialization.

China is considered the largest potential market given tens of thousands of annual EBV-associated nasopharyngeal cancer cases reported there, and the company held a series of meetings with global pharmaceutical majors and large Chinese firms at the BioChina event held in Suzhou in 2026.

Korea implemented its Advanced Regenerative Medicine treatment system in February 2025, and ViGenCell's VT-EBV-N became the first treatment plan approved under the system, marking an early application of regulatory innovation.

This case was also the first instance in which results from an MFDS-regulated commercial clinical trial were used as the basis for a Ministry of Health and Welfare-regulated advanced regenerative medicine treatment plan, which the government has cited as a flagship outcome of its regulatory sandbox program.

Industry-wide, oncology trends focused on relapse prevention — including personalized mRNA cancer vaccines — are gaining global attention, sustaining interest in cell therapies with long-term follow-up data showing relapse-suppression effects.

At the same time, a broader structural issue is emerging across Korea's technology-special-listing biotech sector, as numerous companies approach the end of their five-year post-listing grace period for revenue requirements and face potential administrative-issue designation, independent of clinical progress.

Outlook

The company has set a target of obtaining conditional approval in 2026 and commercializing VT-EBV-N domestically in the first half of 2027.

Toward this, it has referenced a plan to pursue an MFDS fast-track designation after receiving the Phase 2 clinical study report (CSR), with a conditional approval application targeted as early as the second half of the year.

Since September 1, 2026, ongoing treatment under Korea's first approved advanced regenerative medicine plan at Yeouido St. Mary's Hospital is generating additional real-world safety, efficacy, and supply-chain data that could serve as supplementary evidence during the regulatory review process.

In China, licensing discussions with multiple global and local pharmaceutical companies are underway based on Phase 2 data, with the company's business development lead stating that selecting a strategic partner capable of supporting long-term revenue, royalties, and indication expansion into areas such as nasopharyngeal cancer — not just upfront payments — is a priority.

The next-generation iPSC-derived allogeneic CAR-NK platform's glioblastoma-targeting asset, VC-302, continues early-stage development, with preclinical research results presented at the European Society for Medical Oncology.

On the revenue side, 2026Q1 and 2026Q2 revenue rose to about KRW 328.7 million and KRW 571.2 million respectively, approaching the KOSDAQ half-year revenue threshold of KRW 700 million, and second-half revenue trends will be a key variable in determining whether the annual KRW 3 billion requirement is met.

Both the conditional approval process and any China licensing deal remain subject to timeline shifts depending on regulatory review and counterparty negotiations.

Valuation

PER

—

PBR

3.4×

ROE

-29.4%

EPS

-₩648

BPS

₩1,918

Dividend per share

₩0

ViGenCell is a clinical-stage cell therapy company with negligible revenue and multi-year net losses, making conventional earnings-based valuation metrics difficult to apply.

The stock trades at a level reflecting a substantial premium to net asset value, a pattern typical of clinical-momentum biotech names where pipeline value, approval prospects, and licensing expectations weigh more heavily on share pricing than reported earnings.

The company does not pay a dividend, limiting the relevance of dividend-based metrics, and investment focus is likely better placed on non-financial catalysts such as the conditional approval timeline, the outcome of China licensing negotiations, and progress toward the revenue listing requirement.

Given that total equity has declined every year, any future capital raise could affect per-share metrics going forward.

The multi-year earnings trend has remained in a persistent loss-making phase, and how this trajectory evolves alongside the conditional approval and commercialization schedule will be a key focal point ahead.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-05

Bull factors

Consistency of long-term follow-up data

VT-EBV-N met its primary endpoint in Phase 2 with a 2-year disease-free survival rate of 95.0% versus 77.58% in the control arm, and the 4-year follow-up presented at ASCO 2026 showed the same DFS of 95.0% and OS of 100% maintained.

In contrast, the control arm's 4-year DFS fell to 56.3% with six deaths, widening the gap between arms over time. This consistency in long-term data is cited as evidence that the relapse-prevention effect is not a temporary phenomenon, and is seen as potentially favorable input for the conditional approval review.

Pipeline diversification efforts

Beyond its antigen-specific T cell platform, ViGenCell is developing solid-tumor pipeline assets using an iPSC-derived allogeneic CAR-NK platform, including VC-302 targeting glioblastoma and VC-420 targeting hepatocellular carcinoma.

VC-302 preclinical research results have been presented externally at the European Society for Medical Oncology, an early sign of development progress. This is interpreted as an effort to reduce reliance on the single VT-EBV-N asset and expand the business portfolio over the medium to long term.

Ongoing China licensing negotiations

Leveraging its Phase 2 data, ViGenCell participated in the BioChina 2026 event in Suzhou, holding a series of meetings with global pharmaceutical majors and large Chinese firms.

China is considered a strategically important market given its large population of EBV-positive NK/T-cell lymphoma and nasopharyngeal cancer patients, and the company has stated it has engaged a local business-development consulting firm to identify potential partners.

However, deal structure elements such as the upfront-versus-milestone split and the extent of development or manufacturing rights transferred can vary significantly by counterparty, and the final outcome remains undetermined.

Bear factors

End of revenue grace period and administrative-issue-stock concerns

ViGenCell received a five-fiscal-year grace period on the revenue requirement following its technology-special listing in August 2021, but that grace period ends starting in 2026.

With 2025 revenue at only about KRW 22.67 million and cumulative first-half 2026 revenue at roughly KRW 900 million, second-half revenue would need to expand substantially to meet the annual KRW 3 billion threshold.

A Korea IR Service analyst has noted that execution on pipeline commercialization and external revenue expansion will become increasingly important.

Ongoing equity erosion and funding pressure

Total equity has fallen for four consecutive years, from about KRW 89.6 billion in 2022 to KRW 43.7 billion in 2025, alongside recurring annual net losses of roughly KRW 17-18 billion.

Operating cash flow has also been negative in every year, meaning the company likely cannot sustain R&D and commercialization-preparation costs indefinitely without external financing. Should further capital raises occur, dilution of existing shareholders cannot be ruled out.

Uncertainty around approval and commercialization timing

The Phase 2 secondary efficacy endpoint of overall survival (OS) did not reach statistical significance, with a p-value of 0.058, and industry observers note this — combined with the trial being a single-country study in a rare cancer — could face scrutiny during regulatory review.

The current treatment price of about KRW 76.2 million has been confirmed as a temporary promotional rate, meaning pricing could be reset following conditional approval.

If either the conditional approval process or the China licensing effort does not proceed as planned, the targeted first-half-2027 commercialization timeline could be delayed.

Risk factors

Clinical and regulatory risk

VT-EBV-N's secondary efficacy endpoint of overall survival did not reach statistical significance, and the fact that the data comes from a single-country Phase 2 trial in a rare cancer could prompt requests for supplementary evidence during the conditional approval review.

The first advanced regenerative medicine treatment case was also an early instance conducted under a regulatory sandbox exception, leaving limited predictability for how similar cases or follow-on administrative procedures will unfold.

Financial and listing-maintenance risk

With the revenue grace period ending starting in 2026, 2025 revenue was only about KRW 22.67 million, and total equity has declined for four consecutive years.

Failure to meet the annual KRW 3 billion revenue requirement could trigger administrative-issue-stock designation procedures, and any additional capital raise needed to cover ongoing net losses would raise dilution concerns.

Commercialization and partnership risk

A China licensing deal with a low upfront-payment share and high reliance on milestones could limit near-term cash inflows, and the revenue structure could vary significantly depending on the extent of development and manufacturing rights transferred.

Since the initial domestic treatment price of about KRW 76.2 million has been confirmed as a temporary promotional rate, uncertainty remains around future revenue scale following any price reset.

What to watch next

Q4 2026
Whether an MFDS conditional approval application is filed and progress on fast-track designation should be checked. This is a key event for assessing the feasibility of the company's stated 2026 conditional approval and first-half-2027 commercialization targets.
Around November 2026 (Q3 earnings release)
Q3 revenue and progress toward the annual revenue requirement of KRW 3 billion should be checked. Whether the first-half revenue expansion trend continues into the second half will determine the trajectory of administrative-issue-stock designation risk.
Second half of 2026 through early 2027
Whether a China licensing deal is signed, and its upfront-versus-milestone structure and the scope of development or manufacturing rights transferred, should be checked. Deal completion and terms would materially affect future cash flow and business direction.
From Q4 2026 onward
Early real-world treatment data and supply-stability updates from the ongoing advanced regenerative medicine treatment at Yeouido St. Mary's Hospital should be checked, as these could serve as supporting reference material in the future conditional approval review.

Overall view

ViGenCell is accumulating clinical and regulatory milestones — including four-year follow-up data for VT-EBV-N and the launch of Korea's first advanced regenerative medicine treatment — while simultaneously pursuing conditional approval and a China licensing deal.

At the same time, its financial statements reflect the typical profile of a clinical-stage biotech, with four consecutive years of net losses and declining equity, and the end of the revenue-requirement grace period starting in 2026 has emerged as a new variable for listing maintenance.

The clear expansion in revenue in Q1 and Q2 2026 relative to prior quarters can be viewed as a positive signal, but whether the annual KRW 3 billion requirement is met will only be known once second-half results are finalized.

On the China licensing front, only the fact that negotiations are ongoing has been confirmed, with deal terms and completion still undetermined, and the conditional approval review process still faces items requiring further support, such as the lack of statistical significance in the overall survival endpoint.

Investors should weigh the bullish factors of strong clinical data and use of regulatory flexibility against the bearish factors of the revenue requirement, equity erosion, and deal uncertainty in a balanced manner.

Going forward, the conditional approval filing, second-half revenue trends, and progress on the China deal are likely to be the key variables for assessing corporate value.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.